Assessment of Pharmacokinetics and Food Effect of AD-109, a Novel Formulation of Rivaroxaban 18 mg. [PDF]
Clin Transl SciABSTRACT Rivaroxaban is an oral anticoagulant that requires food intake at high doses (15 and 20 mg) due to a pronounced food effect. AD‐109 is a novel formulation of rivaroxaban 18 mg, designed to enhance oral bioavailability and mitigate the food effect.
Ryu H, Cho JY, Lee T, Kim J, Lee S.
europepmc +2 more sources
Stroke Research and Treatment, 2021 Introduction. Rivaroxaban is a new anticoagulant providing benefits for the treatment of patients with atrial fibrillation (AF). This study is aimed at evaluating the cost-effectiveness of rivaroxaban compared to warfarin in patients with AF.
Neda Jaberi +5 more
doaj +1 more source
Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation [PDF]
, 2013 OBJECTIVE: In clinical trials of dabigatran and rivaroxaban for stroke prevention in atrial fibrillation (AF), drug eligibility and dosing were determined using the Cockcroft-Gault equation to estimate creatine clearance as a measure of renal function ...
Ashman, N +6 more
core +3 more sources
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. [PDF]
, 2014 Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in ...
Amarenco, P +6 more
core +2 more sources
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]
, 2019 © The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A +5 more
core +2 more sources
BMC Pharmacology and Toxicology, 2020 Background Rivaroxaban, a novel oral anticoagulant drug, is widely used in clinical practice. There is no standardized laboratory monitoring for rivaroxaban, and its plasma concentration in Chinese patients with deep vein thrombosis is unclear.
Ying Li +4 more
doaj +1 more source
Association Between History of Rhythm Control Therapy and Clinical Outcomes in Atrial Fibrillation Patients With Stable Coronary Artery Disease: A Sub-Analysis of the AFIRE Trial. [PDF]
J ArrhythmIn the AFIRE study, 27% of patients had a history of rhythm control therapy. While unadjusted analyses suggested a benefit, propensity score‐matched results showed no significant difference in the primary efficacy outcome between patients with and without such history.
Wakatsuki D +13 more
europepmc +2 more sources
More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]
, 2018 © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M +6 more
core +3 more sources
Rivaroxaban prescribing in a Saudi tertiary care teaching hospital
Saudi Pharmaceutical Journal, 2018 Purpose: This drug utilization review (DUR) aimed to describe the use of rivaroxaban in a tertiary care teaching hospital and to audit the hospital physicians’ prescribing practice.
Ahmed Yacoob Mayet +3 more
doaj +1 more source
Rivaroxaban and Hemostasis in Emergency Care
Emergency Medicine International, 2014 Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a short half-life. However, confirmation of rivaroxaban
Jürgen Koscielny, Edita Rutkauskaite
doaj +1 more source